ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.Evofosfamide is the only known reducer of solid tumor hypoxia, a...

ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT) Funding will support pre-clinical and clinical development through a Phase 1A/1B trial of IMGS-001, a novel Checkpoint Inhibitor Drug CandidateIMGS-001 has been designed to overcome resistance to...